Literature DB >> 33963566

Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.

Cristina Papayannidis1, Chiara Sartor2, Alida Dominietto3, Elisabetta Zappone4, Mario Arpinati1, Giovanni Marconi2,5, Gianluca Cristiano2, Jacopo Nanni2, Sarah Parisi2, Francesco Barbato2, Stefania Paolini1, Simona Soverini1,2, Carolina Terragna1, Valentina Robustelli2, Nicoletta Testoni1,2, Gabriella Chirumbolo2, Antonio Curti1, Michele Cavo1,2, Francesca Bonifazi1.   

Abstract

Entities:  

Keywords:  acute lymphoblastic leukemia; donor lymphocyte infusion; inotuzumab Ozogamicin; stem cell transplant

Year:  2021        PMID： 33963566     DOI： 10.1002/hon.2886

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  3 in total

Review 1.  Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.

Authors:  Pei-Hua Lu; Kai-Yan Liu; Xing-Yu Cao; Jing-Jing Li
Journal:  Int J Hematol       Date:  2022-06-23       Impact factor: 2.319

2.  Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC.

Authors:  Paul Chauvet; Annalisa Paviglianiti; Myriam Labopin; Hélène Labussière; Nicolas Boissel; Marie Robin; Natacha Maillard; Marie Ouachée-Chardin; Edouard Forcade; Xavier Poiré; Sylvain Chantepie; Anne Huynh; Claude Eric Bulabois; Mathieu Leclerc; Sébastien Maury; Patrice Chevallier; Thomas Cluzeau; Jean-Baptiste Mear; Jérôme Cornillon; Karin Bilger; Célestine Simand; Yves Beguin; Marie-Thérèse Rubio; Ibrahim Yakoub-Agha; Eolia Brissot
Journal:  Bone Marrow Transplant       Date:  2022-10-19       Impact factor: 5.174

Review 3.  Bispecific Antibodies and Other Non-CAR Targeted Therapies and HSCT: Decreased Toxicity for Better Transplant Outcome in Paediatric ALL?

Authors:  Krisztián Miklós Kállay; Mattia Algeri; Jochen Buechner; Aviva C Krauss
Journal:  Front Pediatr       Date:  2022-02-02       Impact factor: 3.418
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.